Neefe J R, Silgals R, Ayoob M, Schein P S
J Biol Response Mod. 1984 Aug;3(4):366-70.
Twenty-one patients with advanced measurable colorectal carcinoma were treated with interferon (rIFN-alpha A) intramuscularly at 50 X 10(6) units/m2 thrice weekly. No patient had received chemotherapy for metastatic or recurrent disease. The average age of the patients was 60 years, and the mean initial performance status was 85 (Karnofsky scale). Nineteen patients were evaluable for response. One patient showed complete resolution of pulmonary nodules and stable liver metastases after 3 months of therapy. The other 18 patients developed progressive disease after 1-3 months of treatment. Toxicity was substantial but manageable; fevers, chills, fatigue, elevated serum glutamic-oxaloacetic transaminase, anemia, and mild leukopenia were common. rIFN-alpha A is minimally active against metastatic colorectal carcinoma.
21例晚期可测量的结肠直肠癌患者接受了干扰素（重组α-A干扰素）治疗，剂量为50×10⁶单位/m²，每周三次，肌肉注射。没有患者因转移性或复发性疾病接受过化疗。患者的平均年龄为60岁，初始平均体能状态为85（卡诺夫斯基量表）。19例患者可评估疗效。1例患者在治疗3个月后肺部结节完全消退，肝转移稳定。其他18例患者在治疗1 - 3个月后病情进展。毒性反应较大但可控；发热、寒战、疲劳、血清谷草转氨酶升高、贫血和轻度白细胞减少很常见。重组α-A干扰素对转移性结肠直肠癌的活性极小。
